Načítá se...
PHRM-01. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE DNA HYPOMETHYLATING AGENT, GUADECITABINE (SGI-110), FOLLOWING SUBCUTANEOUS ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL
BACKGROUND: Guadecitabine, a potent hypomethylating agent currently being studied in clinical trials, is a dinucleotide that is resistant to degradation by cytidine deaminase resulting in an extended release of the active metabolite decitabine following subcutaneous (SC) administration. The CSF expo...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6012492/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.579 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|